Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum

Eli Lilly appears to be making as much of its popular obesity and diabetes medicines as it can, but shortages are worsening , putting the company's earnings at risk, analysts say. Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. The Food and Drug Administration recently reported that supplies of both brands are expected to be limited through the second quarter, for all but one dosage — the introductory 2.

Shin also noted that the there will be some messiness in the first-quarter trends because some of the fourth-quarter sales were pharmacies looking to build up inventory in the wake of Zepbound's approval. Analysts will also been keen to hear about how quickly insurers are adding Zepbound to their list of covered drugs, and how that is impacting realized prices of the drugs.

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli LillyCNBC’s Jim Cramer on Friday walked investors through next week on Wall Street.
Sumber: nbcchicago - 🏆 545. / 51 Baca lebih lajut »

Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli LillyCNBC’s Jim Cramer on Friday walked investors through next week on Wall Street.
Sumber: NBCNewYork - 🏆 270. / 63 Baca lebih lajut »

Eli Lilly weight loss injection drug also helps with obstructive sleep apnea, company saysThe Eli Lilly weight loss injection Zepbound reduced the intensity of obstructive sleep apnea in patients by nearly two-thirds, the pharmaceutical giant announced Wednesday.
Sumber: WashTimes - 🏆 235. / 63 Baca lebih lajut »